Genky DrugStores Co., Ltd. (9267) AI Stock Analysis

• Market Cap: ¥123.86B
• Dividend Yield: 0.32%
• Average Volume (3M): 71.96K
• Price to Earnings (P/E): 18.2
• Beta (1Y): 0.17
• Revenue Growth: 7.83%
• EPS Growth: 14.06%
• Country: JP
• Employees: 1,661
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Pharmaceuticals
• EPS (TTM): 52.79
• Shares Outstanding: 30,996,967
• 10 Day Avg. Volume: 111,880
• 30 Day Avg. Volume: 71,956
• PEG Ratio: 24.43
• Price to Book (P/B): 1.80
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: ―

Genky DrugStores Co., Ltd. demonstrates strong financial performance with robust revenue growth and improved cash flows, which are the primary drivers of the score. Technical analysis suggests bullish momentum, though caution is advised due to overbought signals. Valuation is moderate, with a fair P/E ratio but low dividend yield.

Genky DrugStores Co., Ltd. Business Overview & Revenue Model

Company Description

Genky DrugStores Co., Ltd. (9267) is a Japanese company operating in the retail sector, primarily focused on the pharmacy and drugstore market. It provides a wide range of products including pharmaceuticals, cosmetics, daily necessities, food, and other household items. The company is known for its expansive network of stores across Japan, offering a convenient shopping experience for customers seeking healthcare and lifestyle products.

How the Company Makes Money

Genky DrugStores Co., Ltd. generates revenue through the sale of a diverse array of products in its retail stores. Its primary revenue streams include the sale of pharmaceuticals, over-the-counter medicines, health and beauty products, and everyday consumer goods. The company capitalizes on its extensive store network and strategic locations to attract a steady flow of customers. Additionally, Genky DrugStores may engage in partnerships with suppliers and leverage bulk purchasing to optimize inventory costs and enhance profit margins. The company's focus on customer satisfaction and competitive pricing also plays a crucial role in maintaining its market position and driving sales.

Genky DrugStores Co., Ltd. Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	192.13B	184.86B	169.06B	154.64B	142.38B	123.60B
Gross Profit	39.33B	37.62B	34.55B	30.95B	30.29B	26.71B
EBITDA	15.23B	14.47B	11.73B	10.73B	10.78B	7.86B
Net Income	6.78B	6.32B	4.76B	4.42B	4.83B	2.76B
Balance Sheet
Total Assets	119.92B	113.94B	105.91B	97.12B	90.80B	83.15B
Cash, Cash Equivalents and Short-Term Investments	6.94B	5.90B	5.33B	5.44B	7.91B	6.62B
Total Debt	32.90B	30.65B	32.35B	30.96B	28.56B	30.39B
Total Liabilities	70.12B	67.26B	65.23B	60.88B	58.63B	55.46B
Stockholders Equity	49.79B	46.68B	40.68B	36.23B	32.17B	27.69B
Cash Flow
Free Cash Flow	2.73B	2.81B	-1.16B	-4.43B	3.12B	-3.59B
Operating Cash Flow	2.73B	13.26B	8.77B	6.08B	12.08B	7.41B
Investing Cash Flow	0.00	-10.63B	-9.74B	-10.59B	-8.83B	-11.22B
Financing Cash Flow	0.00	-2.06B	854.00M	2.04B	-1.95B	7.99B

Genky DrugStores Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4035.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9267, the sentiment is Positive. The current price of 4035 is above the 20-day moving average (MA) of 3846.04, above the 50-day MA of 3668.21, and above the 200-day MA of 3252.96, indicating a bullish trend. The MACD of 144.00 indicates Negative momentum. The RSI at 67.38 is Neutral, neither overbought nor oversold. The STOCH value of 69.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:9267.

Genky DrugStores Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3549	76 Outperform	¥410.82B	22.28		0.36%	14.79%	35.84%
9267	75 Outperform	¥123.86B	18.19		0.32%	7.83%	14.06%
7649	75 Outperform	¥685.86B	16.02	16.26%	1.10%	20.18%	82.36%
3141	74 Outperform	¥540.57B	29.46		1.39%	7.43%	-24.81%
9989	74 Outperform	$526.39B	17.12	11.61%	2.89%	6.66%	5.56%
3391	71 Outperform	¥554.14B	25.39	4.93%	3.94%	4.63%	-47.30%
Sector *	64 Neutral	¥343.53B	10.93	-2.99%	2.55%	11.77%	-9.96%

Genky DrugStores Co., Ltd. Corporate Events

Genky DrugStores Reports Strong Financial Performance for Nine Months Ending March 2025

Genky DrugStores Co., Ltd. reported a 7.9% increase in net sales for the nine months ending March 20, 2025, compared to the same period the previous year. The company also saw a 9.4% rise in net income attributable to owners of the parent, reflecting strong operational performance. Despite a stock split implemented in June 2024, the company maintained its financial stability with a slight decrease in its equity ratio. The forecast for the fiscal year ending June 20, 2025, anticipates continued growth with a 9.3% increase in net sales and a 10.7% rise in net income, indicating positive momentum for stakeholders.